Newborn Brain Assessment - CergenX Wave (NBT)
Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software
In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.
A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.
The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Brian Walsh, Neonatologist
- Telefoonnummer: +353214920525
- E-mail: brianhenry.walsh@ucc.ie
Studie Locaties
-
-
Cork
-
Cork, Cork, Ierland
- Werving
- Cork University Maternity Hospital
-
Contact:
- Aisling Fanning
- Telefoonnummer: +353214920525
- E-mail: aisling.fanning1@hse.ie
-
-
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Nog niet aan het werven
- University of Texas Southwestern Medical Center
-
Contact:
- Lina Chalak
- Telefoonnummer: 214-648-3060
- E-mail: Lina.Chalak@UTSouthwestern.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Infants at high-risk of Neonatal Encephalopathy
Beschrijving
Inclusion Criteria:
-
Infants born at ≥36+0 weeks gestational age
-
Informed consent obtained AND
-
A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR
-
a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
-
An APGAR score ≤5 at 10 minutes OR
-
Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR
-
An acute perinatal event:
- Abnormal CTG (variable/late foetal HR decelerations)
- Foetal bradycardia
- Prolapsed/ruptured/tight nuchal cord
- Shoulder dystocia
- Uterine rupture
- Maternal haemorrhage/placental abruption
- Maternal trauma (e.g. vehicle accident)
- Mother received CPR
-
Exclusion Criteria:
- Infants < 36 weeks gestation
- No parental/guardian consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_ONLY
- Tijdsperspectieven: PROSPECTIVE
Aantal groepen / cohorten
Cohorten en interventies
Groep / CohortGroep / Cohort |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Neonates
Neonates at risk of Neonatal Encephalopathy |
The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Tijdsspanne: From the enrolment and up to 6 hours after birth
|
From the enrolment and up to 6 hours after birth
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Tijdsspanne: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Tijdsspanne: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Association between CergenX Wave software and clinical variables including discharge diagnosis
Tijdsspanne: From enrolment of the participant and up to 30 hours after birth
|
Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses |
From enrolment of the participant and up to 30 hours after birth
|
|
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Tijdsspanne: From enrolment of the participant and up to 30 hours after birth
|
An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale. |
From enrolment of the participant and up to 30 hours after birth
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
Andere studie-ID-nummers
- 25116
- DT 2023 0435 (Ander subsidie-/financieringsnummer: Department of Enterprise, Tourism and Employment. Enterprise Ireland)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .